New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimoni...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
2015-06-01
|
| Series: | Revista da Sociedade Brasileira de Medicina Tropical |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822015000300235&lng=en&tlng=en |
| _version_ | 1818554220847038464 |
|---|---|
| author | Miguel Angel Chávez-Fumagalli Tatiana Gomes Ribeiro Rachel Oliveira Castilho Simone Odília Antunes Fernandes Valbert Nascimento Cardoso Cecília Steinberg Perilo Coelho Débora Vasconcelos Costa Mendonça Manuel Soto Carlos Alberto Pereira Tavares André Augusto Gomes Faraco Eduardo Antonio Ferraz Coelho |
| author_facet | Miguel Angel Chávez-Fumagalli Tatiana Gomes Ribeiro Rachel Oliveira Castilho Simone Odília Antunes Fernandes Valbert Nascimento Cardoso Cecília Steinberg Perilo Coelho Débora Vasconcelos Costa Mendonça Manuel Soto Carlos Alberto Pereira Tavares André Augusto Gomes Faraco Eduardo Antonio Ferraz Coelho |
| author_sort | Miguel Angel Chávez-Fumagalli |
| collection | DOAJ |
| description | Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio. |
| first_indexed | 2024-12-12T09:36:31Z |
| format | Article |
| id | doaj.art-f8d70aeae8864101872ee0d579e634db |
| institution | Directory Open Access Journal |
| issn | 1678-9849 |
| language | English |
| last_indexed | 2024-12-12T09:36:31Z |
| publishDate | 2015-06-01 |
| publisher | Sociedade Brasileira de Medicina Tropical (SBMT) |
| record_format | Article |
| series | Revista da Sociedade Brasileira de Medicina Tropical |
| spelling | doaj.art-f8d70aeae8864101872ee0d579e634db2022-12-22T00:28:43ZengSociedade Brasileira de Medicina Tropical (SBMT)Revista da Sociedade Brasileira de Medicina Tropical1678-98492015-06-0148323524210.1590/0037-8682-0138-2015S0037-86822015000300235New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatmentMiguel Angel Chávez-FumagalliTatiana Gomes RibeiroRachel Oliveira CastilhoSimone Odília Antunes FernandesValbert Nascimento CardosoCecília Steinberg Perilo CoelhoDébora Vasconcelos Costa MendonçaManuel SotoCarlos Alberto Pereira TavaresAndré Augusto Gomes FaracoEduardo Antonio Ferraz CoelhoLeishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822015000300235&lng=en&tlng=enAmphotericin BLeishmaniasisNanoparticlesToxicityTreatmentLipid-based formulations |
| spellingShingle | Miguel Angel Chávez-Fumagalli Tatiana Gomes Ribeiro Rachel Oliveira Castilho Simone Odília Antunes Fernandes Valbert Nascimento Cardoso Cecília Steinberg Perilo Coelho Débora Vasconcelos Costa Mendonça Manuel Soto Carlos Alberto Pereira Tavares André Augusto Gomes Faraco Eduardo Antonio Ferraz Coelho New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment Revista da Sociedade Brasileira de Medicina Tropical Amphotericin B Leishmaniasis Nanoparticles Toxicity Treatment Lipid-based formulations |
| title | New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment |
| title_full | New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment |
| title_fullStr | New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment |
| title_full_unstemmed | New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment |
| title_short | New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment |
| title_sort | new delivery systems for amphotericin b applied to the improvement of leishmaniasis treatment |
| topic | Amphotericin B Leishmaniasis Nanoparticles Toxicity Treatment Lipid-based formulations |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822015000300235&lng=en&tlng=en |
| work_keys_str_mv | AT miguelangelchavezfumagalli newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT tatianagomesribeiro newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT racheloliveiracastilho newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT simoneodiliaantunesfernandes newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT valbertnascimentocardoso newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT ceciliasteinbergperilocoelho newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT deboravasconceloscostamendonca newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT manuelsoto newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT carlosalbertopereiratavares newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT andreaugustogomesfaraco newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment AT eduardoantonioferrazcoelho newdeliverysystemsforamphotericinbappliedtotheimprovementofleishmaniasistreatment |